

Keloid

[View the current Keloid InDepth page on BioPortfolio.com](#) ([PDF](#))

(<http://www.bioportfolio.com/indepth/Keloid.html>) - Regularly Updated.

A keloid is a type of scar which results in an overgrowth of tissue at the site of a healed skin injury. Keloids are firm, rubbery lesions or shiny, fibrous nodules and can vary from pink to flesh-colored or red to dark brown in color. A keloid scar is benign, non-contagious and usually accompanied by severe itchiness, sharp pains and changes in texture. In severe cases, it can affect movement of skin. Keloids should not be confused with hypertrophic scars, which are raised scars that do not grow beyond the boundaries of the original wound and may reduce over time. ([From the Wikipedia article Keloid](#).)

Recent Publications on Keloid:



- [Tumor-Like Stem Cells Derived from Human Keloid Are Governed by the Inflammatory Niche Driven by IL-17/IL-6 Axis.](#)
*BACKGROUND: Alterations in the stem cell niche are likely to contribute to...*13th November, 2009
Center for Craniofacial Molecular Biology, School of Dentistry, University- PLoS One. 2009 Nov 11;4(11):e7798. ([DOI Direct Link](#))
- [A Review of the Effectiveness of Antimitotic Drug Injections for Hypertrophic Scars and Keloids.](#)
*Hypertrophic scars and keloids are common problems after injury and cause...*6th November, 2009
From the Institute of Burn, Ruijin Hospital, Jiaotong University Medical- Ann Plast Surg. 2009 Oct 30. ([DOI Direct Link](#))
- [Treatment of a Painful Keloid with Botulinum Toxin Type A.](#)
*Uyesugi B, Lippincott B, Dave S: Treatment of a painful keloid with...*4th November, 2009
From the Department of Physical Medicine and Rehabilitation, Indiana- Am J Phys Med Rehabil. 2009 Oct 30. ([DOI Direct Link](#))
- [Elastic fiber assembly is disrupted by excessive accumulation of chondroitin sulfate in the human dermal fibrotic disease, keloid.](#)
*Keloid is a fibrotic disease characterized by abnormal accumulation of...*3rd November, 2009
Department of Plastic and Reconstructive Surgery, Graduate School of- Biochem Biophys Res Commun. 2009 Oct 29. ([DOI Direct Link](#))
- [Association of HLA-DRB1* and keloid disease in an Afro-Caribbean population.](#)
*Summary Background. Keloid disease (KD) is a fibroproliferative dermal...*31st October, 2009
Plastic and Reconstructive Surgery Research, Dermatological Sciences,- Clin Exp Dermatol. 2009 Oct 23. ([DOI Direct Link](#))
- [Telomere shortening may be associated with human keloids.](#)
*BACKGROUND: Keloids are benign skin tumors that are the effect of a...*30th October, 2009
Department of Life Sciences, University of Naples II, Via Vivaldi 43,- BMC Med Genet. 2009 Oct 28;10:110. ([DOI Direct Link](#))
- [Kimura's disease mimicking an earlobe keloid.](#)

- Summary Kimura's disease (KD) is a rare chronic inflammatory disorder of...* 22nd October, 2009
Department of Dermatology, Taipei Medical University Hospital, Taipei,- Clin Exp Dermatol. 2009 Oct 19. ([DOI Direct Link](#))
- [Adverse effects of a mole removal cream.](#)
Mole removal creams available over the Internet pose potential dangers to... 21st October, 2009
Department of Dermatology, Harvard Medical School, Boston, Massachusetts,- Pediatr Dermatol. 2009 Sep-Oct;26(5):628-9. ([DOI Direct Link](#))
 - [Laser treatment for scars and wounds.](#)
A complex array of reparative tissue mechanisms occur in the skin after... 17th October, 2009
Washington Institute of Dermatologic Laser Surgery, Washington, DC, USA -- G Ital Dermatol Venereol. 2009 Oct;144(5):583-93.
 - [Morphological and immunohistochemical characteristics of atypical fibroxanthoma with a special emphasis on potential diagnostic pitfalls: a review.](#)
The present manuscript gives emphasis on recognizing different... 8th October, 2009
Institute of Pathology, Medical Faculty University of Ljubljana, Korytkova- J Cutan Pathol. 2009 Oct 6. ([DOI Direct Link](#))
 - [\[The effect of tunicamycin on Fas protein expression and its function in fibroblasts from hypertrophic scar and keloid\]](#)
OBJECTIVE: To detect the effect of tunicamycin on Fas protein expression... 7th October, 2009
Department of Plastic Surgery, Nangfang Hospital, Southern Medical- Zhonghua Zheng Xing Wai Ke Za Zhi. 2009 May;25(3):213-6.
 - [\[The interaction between secreted frizzled-related protein 2 and osteoblast-specific factor 2 in keloid\]](#)
OBJECTIVE: To verify the interaction between secreted frizzled-related... 6th October, 2009
Department of Plastic Surgery, Southwest Hospital, the Third Military- Zhonghua Shao Shang Za Zhi. 2009 Apr;25(2):126-8.
 - [\[Expression of Smads in keloid scarring\]](#)
OBJECTIVE: To investigate the differential expression of different types... 29th September, 2009
Department of Burns, the First Affiliated Hospital of Sun Yat-Sen- Zhonghua Wai Ke Za Zhi. 2009 Jun 15;47(12):941-3.
 - [Role of vascular endothelial growth factor in keloids: a clinicopathologic study.](#)
BACKGROUND: Despite their benign nature, keloids are usually associated... 25th September, 2009
Department of Dermatology, Faculty of Medicine, Zagazig University,- Int J Dermatol. 2009 Oct;48(10):1071-7. ([DOI Direct Link](#))
 - [Mechanisms of MAPK pathway mediating TGF-beta\(1\)/Smad signal in keloid fibroblasts.](#)
Summary Background Keloid is recognized as a benign tumor characterized by... 24th September, 2009
Department of Pharmacology, Anhui Medical University, Hefei, 230032,- Br J Dermatol. 2009 Sep 2. ([DOI Direct Link](#))

BioNews Results for Keloid

- [Treatment of a Painful Keloid with Botulinum Toxin Type A](#)
MDLinx: Nov 5 2009 10:28AM Matching: keloid
- [Capstone Therapeutics to Host Conference Call Discussing Third Quarter 2009 Operating Results](#)
Therapeutics Daily: Nov 4 2009 2:58PM Matching: keloid
- [Kimuras disease mimicking an earlobe keloid](#)
MDLinx: Oct 21 2009 10:57AM Matching: keloid
- [Is Radiation Therapy for Keloids Acceptable? The Risk of Radiation-Induced Carcinogenesis](#)
MDLinx: Oct 12 2009 10:42AM Matching: keloid
- [Capstone completes enrollment in second Phase II keloid scarring trial](#)



Keloid Clinical Trials:

- [Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence](#)



Keloid Patents:

- 7565205- [Treating a tumor or the like with electric fields at different orientations](#)
- 7575879- [Polypeptides homologous to VEGF and BMP1](#)
- 7576109- [1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof](#)
- 7579186- [Human monoclonal antibody against TGF-.beta. type II receptor and medicinal use thereof](#)
- 7579337- [Analogues of benzoquinone-containing ansamycins and methods of use thereof](#)
- 7579359- [1-alkoxy 1H-imidazo ring systems and methods](#)
- 7582609- [Method for the treatment of skin fibrosis and suitable compositions for such treatment](#)
- 7582662- [Body weight gain inhibitor](#)
- 7585840- [Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease](#)
- 7588761- [Human antibodies that bind human TNF.alpha.](#)
- 7589083- [Compounds and compositions to control abnormal cell growth](#)
- 7575764- [Compositions comprising hypsizygus ulmarius extract](#)
- 7575751- [Activin-A mutants](#)
- 7572920- [Benzimidazole derivative and use as a II receptor antagonist](#)
- 7565206- [Treating a tumor or the like with electric fields at different orientations](#)
- 7566446- [Wound healing and treatment of fibrosis](#)
- 7566536- [WNT-regulated cytokine-like polypeptide and nucleic acids encoding same](#)
- 7566548- [Methods for identifying therapeutic agents and for treating disease](#)
- 7566706- [Analogues of benzoquinone-containing ansamycins and methods of use thereof](#)
- 7566708- [Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors](#)
- 7569215- [Mutant interleukin-2 \(IL-2\) polypeptides](#)
- 7569384- [Albumin fusion proteins](#)
- 7569571- [Substituted pyrazolo \[3,4-d\]pyrimidines as cytokine modulators](#)
- 7572440- [Method for repairing a defect in an intervertebral disc](#)
- 7592010- [Albumin fusion proteins](#)
- 7592338- [Pyrazole-amine compounds useful as kinase inhibitors](#)
- 7601726- [Substituted pyrazolo\[3,4-d\]pyrimidines as p38 MAP kinase inhibitors](#)
- 7605142- [Expression of cyclin G1 in tumors](#)
- 7605161- [Pyridyl derivatives and their use as therapeutic agents](#)

- 7605273- [Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors](#)
- 7608603- [Substituted pyrazolo\[3,4-D\]pyrimidines as p38 MAP kinase inhibitors](#)
- 7608613- [Analogues of benzoquinone-containing ansamycins and methods of use thereof](#)
- 7608716- [Pyrazolonaphthyridine derivative](#)
- 7612039- [Method of cell growth inhibition with agnoprotein](#)
- 7612080- [GTPase inhibitors and use thereof for controlling platelet hyperactivity](#)
- 7612083- [Urea substituted imidazoquinoline ethers](#)
- 7601512- [Methods for identifying inhibitors of the 20S and 26S proteasome](#)
- 7599745- [Treating a tumor or the like with an electric field](#)
- 7598382- [Aryl substituted imidazoquinolines](#)
- 7592343- [Pyridazine-piperazine compounds and their use as stearyl-CoA desaturase inhibitors](#)
- 7592371- [External preparation](#)
- 7592455- [Bicyclic heteroaromatic compounds as kinase inhibitors](#)
- 7595401- [Therapeutic compounds and their use in cancer](#)
- 7597884- [Hyperglycosylated polypeptide variants and methods of use](#)
- 7598232- [Amino-substituted \(E\)-2,6-dialkoxystryl 4-substituted-benzylsulfones for treating proliferative disorders](#)
- 7598277- [Inhibitors of p38](#)
- 7598281- [Arylcycloalkyl-substituted alkanolic acid derivatives useful as peroxisome proliferator-activated receptor \(PPAR\) ligands for the treatment of hyperlipidemia and diabetes](#)
- 7598348- [Adiponectin receptor variant, AdipoR2v2](#)
- 7598350- [Human anti-epidermal growth factor receptor antibody](#)
- 7612104- [Bicyclic aryl-sulfonic acid \[1,3,4\]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

